Open AccessCardiac Safety Profile of First Dose of Fingolimod for Relapsing-Remitting Multiple Sclerosis in Real-World Settings: Data from a German Prospective Multi-Center Observational Study
Author(s) -
Ralf A. Linker,
Guillaume Wendt
Publication year - 2016
Publication title -
neurology and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.296
H-Index - 19
eISSN - 2193-8253
pISSN - 2193-6536
DOI - 10.1007/s40120-016-0051-7
Subject(s) - fingolimod , medicine , bradycardia , multiple sclerosis , heart rate , asymptomatic , neurology , cardiology , vital signs , sinus bradycardia , qt interval , prospective cohort study , anesthesia , blood pressure , emergency medicine , psychiatry
Fingolimod was the first oral therapy approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). Due to its action on cardiac sphingosine 1-phosphate receptors, fingolimod is leading to a transient decrease in heart rate (HR) and the occurrence of rare and asymptomatic self-limited atrioventricular (AV) blocks. This German non-interventional clinical study aimed to assess the cardiac safety profile in RRMS patients during at least 6 h after the initial treatment or restart after interruption of fingolimod in real-world settings.